Background: Bariatric surgery is the most effective long-term treatment for morbid obesity, reducing obesity-associated co-morbidities. We decide to investigate the role of the polymorphism (G1359A) of the cannabinoid (CB)1 receptor gene on clinical outcomes 1 year after biliopancreatic diversion in morbidly obese patients.
Design: A sample of 66 morbidly obese patients (BMI >40 kg/m2) were operated. Weight, fat mass, blood pressure, basal glucose, triacylglycerols, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol were measured at basal visit and at each visit. The frequency of metabolic comorbidities was recorded at each visit.
Results: Thirty-nine patients (59.1%) had genotype G1359G (wild type group) and 27 (40.9%) patients had genotype G1359A (mutant type group). In wild and mutant type groups, body mass index, weight, waist circumference, systolic blood pressure, glucose, total cholesterol, low-density lipoprotein cholesterol and triacylglycerols concentrations decreased, without statistical between genotype groups. Initial weight percent loss at 1 year of follow up was similar in both genotypes (33.1% vs 33.6%; ns).
Conclusion: The present study demonstrates that polymorphism G1359A in the CB1 receptor did not have a significant effect on biochemical and anthropometric improvements after biliopancreatic diversion surgery.
Corresponding Author: Daniel A. de Luis, MD; e-mail: email@example.comFree PDF Download
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
D.A. de Luis, D. Pacheco, R. Aller, M. González Sagrado, R. Conde, O. Izaola, L. Cuellar, M.C. Terroba, T. Martin, M. Ventosa
G1359A polymorphism of the cannabinoid receptor gene (CNR1) and clinical results of biliopancreatic diversion
Eur Rev Med Pharmacol Sci
Vol. 14 - N. 3